Pfizer Balance Sheet Health
Financial Health criteria checks 3/6
Pfizer has a total shareholder equity of $92.6B and total debt of $67.9B, which brings its debt-to-equity ratio to 73.4%. Its total assets and total liabilities are $219.5B and $126.9B respectively. Pfizer's EBIT is $11.5B making its interest coverage ratio 7.1. It has cash and short-term investments of $10.0B.
Key information
73.4%
Debt to equity ratio
US$67.95b
Debt
Interest coverage ratio | 7.1x |
Cash | US$9.95b |
Equity | US$92.56b |
Total liabilities | US$126.92b |
Total assets | US$219.48b |
Recent financial health updates
No updates
Recent updates
Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call
Dec 18Pfizer's (NYSE:PFE) Dividend Will Be Increased To $0.43
Dec 16Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns
Dec 11Pfizer: Too Cheap To Ignore
Dec 05Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks
Nov 21Big Pharma Reckoning Looms With RFK Jr. Eyeing Pfizer
Nov 15Some Investors May Be Willing To Look Past Pfizer's (NYSE:PFE) Soft Earnings
Nov 13Pfizer: Discounted For A Reason - But Dividend Story Remains Rich
Nov 08Pfizer Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 01Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed
Oct 29Pfizer: Activists Clouding A Promising Picture
Oct 21Pfizer: A Strong Product Pipeline Could Lead To Significant Upside
Oct 08Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'
Oct 01There's Reason For Concern Over Pfizer Inc.'s (NYSE:PFE) Price
Sep 23Pfizer: Undervalued Healthcare Leader Poised For Further Recovery
Sep 23Financial Position Analysis
Short Term Liabilities: PFE's short term assets ($43.2B) exceed its short term liabilities ($43.2B).
Long Term Liabilities: PFE's short term assets ($43.2B) do not cover its long term liabilities ($83.7B).
Debt to Equity History and Analysis
Debt Level: PFE's net debt to equity ratio (62.7%) is considered high.
Reducing Debt: PFE's debt to equity ratio has reduced from 80.5% to 73.4% over the past 5 years.
Debt Coverage: PFE's debt is not well covered by operating cash flow (16.6%).
Interest Coverage: PFE's interest payments on its debt are well covered by EBIT (7.1x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 08:37 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/29 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pfizer Inc. is covered by 55 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
David Toung | Argus Research Company |
Ishan Majumdar | Baptista Research |
Alistair Campbell | Berenberg |